Alain Vandormael1,2,3, Till Bärnighausen2,4,5,6, Joshua Herbeck7, Andrew Tomita1,2,3, Andrew Phillips8, Deenan Pillay2,9, Tulio de Oliveira3,10, Frank Tanser1,2,6,10. 1. School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa. 2. Africa Health Research Institute, Durban, South Africa. 3. Kwazulu-Natal Research Innovation and Sequencing Platform, University of KwaZulu-Natal, Durban, South Africa. 4. Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 5. Heidelberg Institute for Public Health, Faculty of Medicine, University of Heidelberg, Germany. 6. Research Department of Infection and Population Health, University College London, United Kingdom. 7. International Clinical Research Center, Department of Global Health, University of Washington, Seattle. 8. Institute for Global Health, United Kingdom. 9. Division of Infection and Immunity, University College London, United Kingdom. 10. Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
Abstract
Background: The prevalence of detectable viremia has previously been used to infer the potential for ongoing human immunodeficiency virus (HIV) transmission. To date, no study has evaluated the longitudinal change in the prevalence of detectable viremia within the HIV-positive community (PDV+) and the entire population (PDVP) using data from a sub-Saharan African setting. Methods: In 2011, 2013, and 2014, we obtained 6752 HIV-positive and 15415 HIV-negative test results from a population-based surveillance system in the KwaZulu-Natal province of South Africa. We quantified the PDV+ as the proportion of the 6752 HIV-positive results with a viral load >1550 copies/mL and the PDVP as the proportion of the 6752 HIV-positive and 15415 HIV-negative results with a viral load >1550 copies/mL. Results: Between 2011 and 2014, the PDV+ decreased by 16.5 percentage points (pp) for women (from 71.8% to 55.3%) and 10.6 pp for men (from 77.8% to 67.2%). However, a steady rise in the overall HIV prevalence, from 26.7% to 32.4%, offset the declines in the PDV+ for both sexes. For women, the PDVP decreased by only 2.1 pp, from 21.3% to 19.2%, but for men, the PDVP actually increased by 1.6 pp, from 14.6% to 16.2%, over the survey period. Conclusions: The PDV+, which is currently being tracked under the UNAIDS 90-90-90 targets, may not be an accurate indicator of the potential for ongoing HIV transmission. There is a critical need for countries to monitor and report the prevalence of detectable viremia among all adults, irrespective of HIV status.
Background: The prevalence of detectable viremia has previously been used to infer the potential for ongoing human immunodeficiency virus (HIV) transmission. To date, no study has evaluated the longitudinal change in the prevalence of detectable viremia within the HIV-positive community (PDV+) and the entire population (PDVP) using data from a sub-Saharan African setting. Methods: In 2011, 2013, and 2014, we obtained 6752 HIV-positive and 15415 HIV-negative test results from a population-based surveillance system in the KwaZulu-Natal province of South Africa. We quantified the PDV+ as the proportion of the 6752 HIV-positive results with a viral load >1550 copies/mL and the PDVP as the proportion of the 6752 HIV-positive and 15415 HIV-negative results with a viral load >1550 copies/mL. Results: Between 2011 and 2014, the PDV+ decreased by 16.5 percentage points (pp) for women (from 71.8% to 55.3%) and 10.6 pp for men (from 77.8% to 67.2%). However, a steady rise in the overall HIV prevalence, from 26.7% to 32.4%, offset the declines in the PDV+ for both sexes. For women, the PDVP decreased by only 2.1 pp, from 21.3% to 19.2%, but for men, the PDVP actually increased by 1.6 pp, from 14.6% to 16.2%, over the survey period. Conclusions: The PDV+, which is currently being tracked under the UNAIDS 90-90-90 targets, may not be an accurate indicator of the potential for ongoing HIV transmission. There is a critical need for countries to monitor and report the prevalence of detectable viremia among all adults, irrespective of HIV status.
Authors: Amanda D Castel; Montina Befus; Sarah Willis; Angelique Griffin; Tiffany West; Shannon Hader; Alan E Greenberg Journal: AIDS Date: 2012-01-28 Impact factor: 4.177
Authors: Julio S G Montaner; Viviane D Lima; Rolando Barrios; Benita Yip; Evan Wood; Thomas Kerr; Kate Shannon; P Richard Harrigan; Robert S Hogg; Patricia Daly; Perry Kendall Journal: Lancet Date: 2010-07-16 Impact factor: 79.321
Authors: Vivek Jain; Teri Liegler; Jane Kabami; Gabriel Chamie; Tamara D Clark; Douglas Black; Elvin H Geng; Dalsone Kwarisiima; Joseph K Wong; Mohamed Abdel-Mohsen; Nitin Sonawane; Francesca T Aweeka; Harsha Thirumurthy; Maya L Petersen; Edwin D Charlebois; Moses R Kamya; Diane V Havlir Journal: Clin Infect Dis Date: 2012-12-12 Impact factor: 9.079
Authors: Moupali Das; Priscilla Lee Chu; Glenn-Milo Santos; Susan Scheer; Eric Vittinghoff; Willi McFarland; Grant N Colfax Journal: PLoS One Date: 2010-06-10 Impact factor: 3.240
Authors: Evan Wood; Thomas Kerr; Brandon D L Marshall; Kathy Li; Ruth Zhang; Robert S Hogg; P Richard Harrigan; Julio S G Montaner Journal: BMJ Date: 2009-04-30
Authors: Andrew Tomita; Alain Vandormael; Till Bärnighausen; Andrew Phillips; Deenan Pillay; Tulio De Oliveira; Frank Tanser Journal: AIDS Date: 2019-03-01 Impact factor: 4.177
Authors: Adam Akullian; Alain Vandormael; Joel C Miller; Anna Bershteyn; Edward Wenger; Diego Cuadros; Dickman Gareta; Till Bärnighausen; Kobus Herbst; Frank Tanser Journal: Proc Natl Acad Sci U S A Date: 2021-07-13 Impact factor: 12.779
Authors: Alain Vandormael; Diego Cuadros; Adrian Dobra; Till Bärnighausen; Frank Tanser Journal: BMC Public Health Date: 2020-08-06 Impact factor: 3.295
Authors: Alain Vandormael; Adam Akullian; Mark Siedner; Tulio de Oliveira; Till Bärnighausen; Frank Tanser Journal: Nat Commun Date: 2019-12-02 Impact factor: 14.919